Atanasio
Pandiella Alonso
Centro de Investigación Biomédica en Red de Cáncer
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (21)
2024
-
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression
International Journal of Molecular Sciences, Vol. 25, Núm. 6
2022
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
-
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
Biomolecules, Vol. 12, Núm. 11
-
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Therapeutic Advances in Medical Oncology, Vol. 14
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679
2021
-
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
npj Precision Oncology, Vol. 5, Núm. 1
-
Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer
Cancers, Vol. 13, Núm. 16
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation
International Journal of Molecular Sciences, Vol. 22, Núm. 8
2020
-
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Breast Cancer Research, Vol. 22, Núm. 1
-
Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis
Molecular Diagnosis and Therapy, Vol. 24, Núm. 2, pp. 143-151
-
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127
-
Proteolysis targeting chimeras (PROTACs) in cancer therapy
Journal of Experimental and Clinical Cancer Research, Vol. 39, Núm. 1
2019
-
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
-
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome
OncoImmunology, Vol. 8, Núm. 10
-
Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
Frontiers in Oncology, Vol. 9
-
Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis
Cancer Treatment Reviews, Vol. 77, pp. 11-19
-
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells
Cancer Letters, Vol. 453, pp. 34-44
2018
-
Refining Early Antitumoral Drug Development
Trends in Pharmacological Sciences
2017
-
Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
Molecular Oncology, Vol. 11, Núm. 12, pp. 1788-1805